Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

E. J. Small; D. Cella; K. McQuarrie; F. Saad; B. A. Hadaschik; J. N. Graff; H. Uemura; S. Oudard; M. K. Yu; S. Hudgens; A. Lopez-Gitlitz; B. Rooney; M. Morris; M. R. Smith

doi:10.1093/annonc/mdy284.013

Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

E. J. Small, D. Cella, K. McQuarrie, F. Saad, B. A. Hadaschik, J. N. Graff, H. Uemura, S. Oudard, M. K. Yu, S. Hudgens, A. Lopez-Gitlitz, B. Rooney, M. Morris, M. R. Smith

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii276-viii277
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy284.013
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy284.013

Cite this

Small, E. J., Cella, D., McQuarrie, K., Saad, F., Hadaschik, B. A., Graff, J. N., Uemura, H., Oudard, S., Yu, M. K., Hudgens, S., Lopez-Gitlitz, A., Rooney, B., Morris, M., & Smith, M. R. (2018). Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii276-viii277. https://doi.org/10.1093/annonc/mdy284.013

Research output: Contribution to journal › Article › peer-review

Small, EJ, Cella, D, McQuarrie, K, Saad, F, Hadaschik, BA, Graff, JN, Uemura, H, Oudard, S, Yu, MK, Hudgens, S, Lopez-Gitlitz, A, Rooney, B, Morris, M & Smith, MR 2018, 'Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii276-viii277. https://doi.org/10.1093/annonc/mdy284.013

Small EJ, Cella D, McQuarrie K, Saad F, Hadaschik BA, Graff JN et al. Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii276-viii277. doi: 10.1093/annonc/mdy284.013

Small, E. J. ; Cella, D. ; McQuarrie, K. et al. / Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN : A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii276-viii277.

@article{c8b221a18b014414a54aa364ebccfdb9,

title = "Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)",

author = "Small, {E. J.} and D. Cella and K. McQuarrie and F. Saad and Hadaschik, {B. A.} and Graff, {J. N.} and H. Uemura and S. Oudard and Yu, {M. K.} and S. Hudgens and A. Lopez-Gitlitz and B. Rooney and M. Morris and Smith, {M. R.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy284.013",

language = "English (US)",

volume = "29",

pages = "viii276--viii277",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN

T2 - A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

AU - Small, E. J.

AU - Cella, D.

AU - McQuarrie, K.

AU - Saad, F.

AU - Hadaschik, B. A.

AU - Graff, J. N.

AU - Uemura, H.

AU - Oudard, S.

AU - Yu, M. K.

AU - Hudgens, S.

AU - Lopez-Gitlitz, A.

AU - Rooney, B.

AU - Morris, M.

AU - Smith, M. R.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081531856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081531856&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy284.013

DO - 10.1093/annonc/mdy284.013

M3 - Article

C2 - 32136633

SN - 0923-7534

VL - 29

SP - viii276-viii277

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this